Are Analysts Bearish Sagent Pharmaceuticals Inc (NASDAQ:SGNT) After Last Week?

Out of 7 analysts covering Sagent Pharmaceuticals (NASDAQ:SGNT), 4 rate it “Buy”, 0 “Sell”, while 5 “Hold”. This means 44% are positive. $28 is the highest target while $15 is the lowest. The $20.71 average target is 91.76% above today’s ($12.62) stock price. Sagent Pharmaceuticals was the topic in 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Deutsche Bank maintained the stock on January 12 with “Buy” rating. JP Morgan reinitiated the shares of SGNT in a report on January 6 with “Neutral” rating. Below is a list of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) latest ratings and price target changes.

12/01/2016 Broker: Raymond James Rating: Strong Buy Old Target: $30.00 New Target: $25.00 Target Down
12/01/2016 Broker: Deutsche Bank Rating: Buy Old Target: $21.0 New Target: $18.0 Maintain
12/01/2016 Broker: RBC Capital Markets Rating: Outperform Old Target: $34.0 New Target: $28.0 Maintain
06/01/2016 Broker: JP Morgan Rating: Neutral Reinitiate
04/11/2015 Broker: Jefferies Rating: Hold Old Target: $24.00 New Target: $18.00 Target Down

The stock decreased 0.24% or $0.03 on April 8, hitting $12.62. About 252,866 shares traded hands. Sagent Pharmaceuticals Inc (NASDAQ:SGNT) has declined 36.36% since September 2, 2015 and is downtrending. It has underperformed by 41.43% the S&P500.

Sagent Pharmaceuticals, Inc. , formerly Sagent Holding Co., is an injectable pharmaceutical firm that develops and sources products that the Company sells primarily in the United States. The company has a market cap of $200.90 million. Sagent focuses primarily on generic injectable pharmaceuticals. It currently has negative earnings. Sagent offers its clients a range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled, ready-to-use syringes, medical devices and premix bags.

The institutional sentiment decreased to 0.92 in 2015 Q3. Its down 0.83, from 1.75 in 2015Q2. The ratio dropped, as 31 funds sold all Sagent Pharmaceuticals Inc shares owned while 43 reduced positions. 15 funds bought stakes while 53 increased positions. They now own 23.30 million shares or 6.20% less from 24.84 million shares in 2015Q2.

Longwood Capital Partners Llc holds 1.62% of its portfolio in Sagent Pharmaceuticals Inc for 182,618 shares. Healthcor Management L.P. owns 1.25 million shares or 1.08% of their US portfolio. Moreover, Penn Capital Management Co Inc has 0.95% invested in the company for 1.18 million shares. The Connecticut-based Thomson Horstmann & Bryant Inc has invested 0.87% in the stock. Piermont Capital Management Inc., a Missouri-based fund reported 140,360 shares.

Sagent Pharmaceuticals Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.

Add Comment